Bone matrix osteonectin limits prostate cancer cell growth and survival

Matrix Biology

Volumn 31, Issue 5, 2012, Pages 299-307

  Kapinas, Kristina ^a   Lowther, Katie M ^a   Kessler, Catherine B ^a   Tilbury, Karissa ^b   Lieberman, Jay R ^a   Tirnauer, Jennifer S ^a   Campagnola, Paul ^b   Delany, Anne M ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b University of Wisconsin Madison   (United States)

Author keywords

Bone metastasis; Collagen; Prostate cancer; Radioresistance; Second harmonic generation imaging; Sparc

Indexed keywords

COLLAGEN; COLLAGEN FIBER; OSTEONECTIN;

ANIMAL CELL; ARTICLE; BASEMENT MEMBRANE; BONE MATRIX; BONE METASTASIS; CANCER CELL CULTURE; CANCER GROWTH; CELL DEATH; CELL PROLIFERATION; CELL SPREADING; CELL SURVIVAL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; PROSTATE CANCER;

ANIMALS; BLOTTING, WESTERN; BONE MATRIX; CELL COMMUNICATION; CELL DEATH; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SHAPE; CELL SURVIVAL; GAMMA RAYS; MALE; MICE; OSTEOBLASTS; OSTEONECTIN; PROSTATIC NEOPLASMS; RECOMBINANT PROTEINS; TUMOR MICROENVIRONMENT;

EID: 84861655007     PISSN: 0945053X     EISSN: 15691802     Source Type: Journal    
DOI: 10.1016/j.matbio.2012.03.002     Document Type: Article

References (65)

1. Bellows C.G., Aubin J.E., Heersche J.N., Antosz M.E. Mineralized bone nodules formed in vitro from enzymatically released rat calvaria cell populations. Calcif. Tissue Int. 1986, 38:143-154.
2. Berquin I.M., Min Y., Wu R., Wu H., Chen Y.Q. Expression signature of the mouse prostate. J. Biol. Chem. 2005, 280. (3644236451).
3. Bianco P. Bone and the hematopoietic niche: a tale of two stem cells. Blood 2011, 19:5281-5288.
4. Bradshaw A.D. The role of SPARC in extracellular matrix assembly. J. Cell Commun. Signal. 2009, 3:239-246.
5. Chen N., Ye X.-C., Chu K., Navone N.M., Sage E.H., Yu-Lee L.-Y., Logothetis C.J., Lin S.-H. A secreted isoform of ErbB3 promotes osteonectin expression in bone and enhances the invasiveness of prostate cancer cells. Cancer Res. 2007, 67:6544-6548.
6. Chung L.W.K., Baseman A., Assikis V., Zhau H.E. Molecular insights into prosate cancer progression: the missing link of tumor microenvironment. J. Urol. 2005, 173:10-20.
7. 3 in prostate cancer progression. Neoplasia 2002, 3:191-194.
8. De S., Chen J., Narizhneva N.V., Heston W., Brainard J., Sage E.H., Byzova T.V. Molecular pathway for cancer metastasis to bone. J. Biol. Chem. 2003, 278:39044-39050.
9. Delany A.M., Amling M., Priemel M., Howe C.C., Baron R., Canalis E. Osteopenia and decreased bone formation in osteonectin-deficient mice. J. Clin. Invest. 2000, 105:915-923.
10. Delany A.M., Hankenson K.D. Thrombospondin-2 and osteonectin/SPARC are critical regulators of bone remodeling. J. Cell Commun. Signal. 2009, 3:227-238.
11. Delany A.M., Kalajzic I., Bradshaw A.D., Sage E.H., Canalis E. Osteonectin-null mutation compromises osteoblast formation, maturation, and survival. Endocrinology 2003, 144:2588-2596.
12. Delany A.M., McMahon D., Powell J.S., Greenberg D.A., Kurland E.S. Osteonectin/SPARC polymorphisms in Caucasian men with idiopathic osteoporosis. Osteoporos. Int. 2008, 19:969-973.
13. Dhanasekaran S.M., Barrette T.R., Ghosh D., Shah R., Varambally S., Kurachi K., Pienta K.J., Rubin M.A., Chinnaiyan A.M. Delineation of prognostic biomarkers in prostate cancer. Nature 2001, 412:822-826.
14. Di Lullo G.A., Sweeney S.M., Körkkö J., Ala-Kokko L., San Antonino J.D. Mapping of the ligand-binding sites and disease-associated mutations on the most abundant protein in the human, type I collage. J. Biol. Chem. 2002, 277:4223-4231.
15. Docheva D., Padula D., Schieker M., Clausen-Schaumann H. Effect of collagen I and fibronectin on the adhesion, elasticity and cytoskeletal organization of prostate cancer cells. Biochem. Biophys. Res. Commun. 2010, 402:361-366.
16. Feeley B.T., Gamradt S.C., Hsu W.K., Liu N., Krenek L., Robbins P., Huard J., Lieberman J.R. Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer. J. Bone Miner. Res. 2005, 20:2189-2199.
17. Gabbitas B., Canalis E. Insulin-like growth factors sustain insulin-like growth factor-binding protein-5 expression in osteoblasts. Am. J. Physiol. 1998, 275(2 Pt 1):E222-E228.
18. Gingrich J.R., Barrios R.J., Morton R.A., Boyce B.F., DeMayo F.J., Finegold M.J., Angelopoulou R., Rosen J.M., Greenberg N.M. Metastatic prostate cancer in a transgenic mouse. Cancer Res. 1996, 56:4096-4102.
19. 1) signaling promotes the growth of human prostate cancer cells within the bone. Cancer Res. 2006, 66:8648-8654.
20. Ingram R.T., Clarke B.L., Fisher L.W., Fitzpatrick L.A. Distribution of noncollagenous proteins in the matrix of adult human bone: evidence of anatomic and functional heterogeneity. J. Bone Miner. Res. 1993, 8:1019-10122.
21. Jacob K., Webber M., Benayahu D., Kleinman H.K. Osteonectin promotes prostate cancer cell immigration and invasion: a possible mechanism for metastasis to bone. Cancer Res. 1999, 59:4453-4457.
22. Janmey P.A., Winer J.P., Murray M.E., Wen Q. The hard life of soft cells. Cell Motil. Cytoskeleton 2009, 66:597-605.
23. Jean C., Gravelle P., Fournie J.-J., Laurent G. Influence of stress on extracellular matrix and integrin biology. Oncogene 2011, 30:2697-2706.
24. Kaighn M.E., Narayan K.S., Ohnuki Y., Lechner J.F., Jones L.W. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest. Urol. 1979, 17:6-23.
25. Kalajzic I., Staal A., Yang W.P., Wu Y., Johnson S.E., Feyen J.H., Krueger W., Maye P., Yu F., Zhao Y., Kuo L., Gupta R.R., Achenie L.E., Wang H.W., Shin D.G., Rowe D.W. Expression profile of osteoblast lineage at defined stages of differentiation. J. Biol. Chem. 2005, 280:24618-24626.
26. Kapinas K., Kessler C.B., Delany A.M. miR-29 suppression of osteonectin in osteoblasts: regulation during differentiation and by canonical wnt signaling. J. Cell. Biochem. 2009, 108:216-224.
27. Kessler C.B., Delany A.M. Increased notch 1 expression and attenuated stimulatory G protein coupling to adenylyl cyclase in osteonectin-null osteoblasts. Endocrinology 2008, 148:1666-1674.
28. Kim D.-H., Nan K., Gupta K., Kwon K.W., Suh K.-Y., Levchenko A. Mechanosensitivity of fibroblast cell shape and movement to anisotropic substratum topography gradients. Biomaterials 2009, 30:5433-5444.
29. Kong Z., Xie D., Boike T., Raghavan P., Burma S., Chen D.J., Habib A.A., Chakraborty A., Hsieh J.-T., Saha D. Downregulation of human DAB2IP gene expression in prostate cancer cells results in resistance to ionizing radiation. Cancer Res. 2010, 70:2829-2839.
30. Lacomb R., Nadiarnykh O., Campagnola P.J. Quantitative second harmonic generation imaging of diseased state osteogenesis imperfecta: experiment and simulation. Biophys. J. 2008, 94:4504-4515.
31. Larsen M., Artym V.V., Green J.A., Yamada K.M. The matrix reorganized: extracellular matrix remodeling and integrin signaling. Curr. Opin. Cell Biol. 2006, 18:463-471.
32. Lee Y.-P., Schwartz E.M., Davies M., Jo M., Gates J., Zhang X., Wu J., Lieberman J.R. Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model. Cancer Res. 2002, 62:5564-5570.
33. Lin S.-H., Cheng C.-J., Lee Y.-C., Ye X., Tsai W.-W., Kim J., Pasqualini R., Arap W., Navone N.M., Tu S.-M., Hu M., Yu-Lee L.-Y., Logothetis C.J. A 45-kDa ErbB3 secreted by prostate cancer cells promotes bone formation. Oncogene 2008, 27:5195-5203.
34. Machado do Reis L., Kessler C.B., Adam s.D.J., Lorenzo J., Jorgetti V., Delany A.M. Accentuated osteoclastic response to parathyroid hormone undermines bone mass acquisition in osteonectin-null mice. Bone 2008, 43:264-273.
35. Malaval L., Fournier B., Delmas P.D. Radioimmunoassay for osteonectin. Concentrations in bone, nonmineralized tissues, and blood. J. Bone Miner. Res. 1987, 2:457-465.
36. Mannino M., Chalmers A.J. Radioresistance of glioma stem cells: Intrinsic characteristic or property of the "microenvironment-stem cell unit'?. Mol. Oncol. 2011, 5:374-386.
37. McCabe N.P., Kerr B.A., Madajka M., Vasanji A., Byzova T.V. Augmented osteolysis in SPARC-deficient mice with bone-residing prostate cancer. Neoplasia 2011, 13:31-39.
38. Midwood K.S., Orend G. The role of tenascin-C in tissue injury and tumorigenesis. J Cell Commun. Signal. 2009, 3:287-310.
39. Moro L., Arbini A.A., Marra E., Greco M. Down-regulation of BRCA2 expression by collagen type I promotes prostate cancer cell proliferation. J. Biol. Chem. 2005, 280:22482-22491.
40. Nadiarnykh O., Plotnikov S., Mohler W.A., Kalajzic I., Redford-Badwal D., Campagnola P.J. Second harmonic generation imaging microscopy studies of osteogenesis imperfecta. J. Biomed. Opt. 2007, 12:051805.
41. Pienta K.J., Abate-Shen C., Agus D.B., Attar R.M., Chung L.W., Greenberg N.M., Hahn W.C., Isaacs J.T., Navone N.M., Peehl D.M., Simons J.W., Solit D.B., Soule H.R., VanDyke T.A., Weber M.J., Wu L., Vessella R.L. The current state of preclinical prostate cancer animal models. Prostate 2008, 68:629-639.
42. Podgorski I., Linebaugh B.E., Klobinski J.E., Rudy D.L., Herroon M.K., Olive M.B., Sloane B.F. Bone marrow-derived capthesin K cleaves SPARC in bone metastasis. Am. J. Pathol. 2009, 175:1255-1269.
43. Poincioux R., Lizárraga F., Chavrier P. Matrix invasion by tumour cells: a focus on MT1-MMP trafficking to invadopodia. J. Cell Sci. 2009, 122:3015-3024.
44. Roudier M.P., Morrissey C., True L.D., Higano C.S., Vessella R.L., Ott S.M. Histopathological assessment of prostate cancer bone osteoblastic metastases. J. Urol. 2008, 180:1154-1160.
45. Robey P.G., Boskey A.L., Lian J.B., Goldring S.R. Chapter 3. Extracellular Matrix and Biomineralization of Bone. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism 2006, 6:12-19.
46. Sage E.H., Reed M., Funk S.E., Truong T., Steadele M., Puolakkainen P., Maurice D.H., Bassuk J.A. Cleavage of the matricellular protein SPARC by matrix metalloproteinase 3 produces polypeptides that influence angiogenesis. J. Biol. Chem. 2003, 278:37849-37857.
47. Said N., Frierson H.F., Chernauskas D., Motamed K., Theodorescu D. The role of SPARC in the TRAMP model of prostate carcinogenesis and progression. Oncogene 2009, 28:3487-3498.
48. Sasaki T., Göhring W., Mann K., Maurer P., Hohenester E., Knäuper V., Murphy G., Timpl R. Limited cleavage of extracellular matrix protein BM-40 by matrix metalloproteinases increases its affinity for collagens. J. Biol. Chem. 1997, 272:9237-9243.
49. Shiozawa Y., Pedersen E.A., Havens A.M., Jung Y., Mishra A., Joseph J., Kim J.K., Patel L.R., Ying C., Ziegler A.M., Pienta M.J., Song J., Wang J., Loberg R.D., Krebsbach P.H., Pienta K.J., Taichman R.S. Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J. Clin. Invest. 2011, 121:1298-1312.
50. Singh S., Singh G. Overview Bone Metastasis: Experimental and Clinical Therapeutics 2005, 3-12. Humana Press, Totowa, NJ. G. Singh, S.A. Rabbani (Eds.).
51. Sobel R.E., Sadar M.D. Cell lines used in prostate cancer research: a compendium of old and new lines-part 1. J. Urol. 2005, 173:342-359.
52. Storch K., Eke I., Borgmann K., Krause M., Richter C., Becker K., Schröck E., Cordes N. Three-dimensional cell growth confers radioresistance by chromatin density modification. Cancer Res. 2010, 70:3925-3934.
53. Sung S.Y., Hsieh C.L., Law A., Zhau H.E., Pathak S., Multani A.S., Lim S., Coleman I.M., Wu L.C., Figg W.D., Dahut W.L., Nelson P., Lee J.K., Amin M.B., Lyles R., Johnstone P.A., Marshall F.F., Chung L.W. Coevolution of prostate cancer and bone stroma in three-dimensional cocutlure: implications for cancer growth and metastasis. Cancer Res. 2008, 68:9996-10003.
54. Sweeney S.M., Orgel J.P., Fertala A., McAuliffe J.D., Turner K.R., Di Lullo G.A., Chen S., Antipova O., Perumal S., Ala-Koko L., Forlino A., Cabral W.A., Barnes A.M., Marini J.C., San Antonio J.D. Candidate cell and matrix interaction domains on the collagen fibril, the predominant protein of vertebrates. J. Biol. Chem. 2008, 283:21187-21197.
55. Tai I.T., Dai M., Owen D.A., Chen L.B. Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy. J. Clin. Invest. 2005, 115:1492-1502.
56. Teixeira A.I., Abrams G.A., Bertics P.J., Murphy C.J., Nealey P.F. Epithelial contact guidance on well-defined micro- and nanostructured substrates. J. Cell Sci. 2003, 116:1881-1892.
57. Thomas R., True L.K., Bassuk J.A., Lang P.H., Vessella R.L. Differential expression of osteonectin/SPARC during human prostate cancer progression. Clin. Cancer Res. 2000, 6:1140-1149.
58. Tilghman R.W., Cowan C.R., Mih J.D., Koryakina Y., Gioeli D., Slack-Davis J.K., Blackman B.R., Tschumperlin D.J., Parsons J.T. PLoS One 2010, 5:e12905.
59. Weidhaas J.B., Babar I., Nallur S.M., et al. MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy. Cancer Res. 2007, 67:11111-11116.
60. Wolf K., Alexander S., Schact V., Coussens L.M., von Andrian U.H., van Rheenen J., Deryugina E., Friedl P. Collagen-based cell migration models in vitro and in vivo. Semin. Cell Dev. Biol. 2009, 20:931-941.
61. Wong S.Y., Crowley D., Bronson R.T., Hynes R.O. Analysis of the role of endogenous SPARC in mouse models of prostate and breast cancer. Clin. Exp. Metastasis 2008, 25:109-118.
62. Yim E.K.F., Leong K.W. Significance of synthetic nanostructures in dictating cellular response. Nanomedicine 2005, 1:10-21.
63. Zhang P., Singh A., Yegnasubramanian S., Esopi D., Kombairaju P., Bodas M., Wu H., Bova S.G., Biswal S. Loss of kelch-like ECH-associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth. Mol. Cancer Ther. 2010, 9:336-346.
64. Zhang W., Pantschenko A.G., McCarthy M.B., Gronowicz G. Bone-targeted overexpression of Bcl-2 increases osteoblast adhesion and differentiation and inhibits mineralization in vitro. Calcif. Tissue Int. 2007, 80:111-122.
65. Zhivkova-Galunska M., Adwan H., Eyol E., Kleeff J., Kolb A., Bergmann F., Berger M.R. Osteopontin but not osteonectin favors the metastatic growth of pancreatic cancer cell lines. Cancer Biol. Ther. 2010, 10:54-64.